您的位置: 首页 > 农业专利 > 详情页

VEGF to use in the treatment of disorders of the central nervous system
专利权人:
NEWRON SWEDEN AB
发明人:
DELFANI, KIOUMARS,JANSON LANG, ANN MARIE,KUHN, HANS-GEORG,PLATE, KARLHEINZ,SCHÄNZER, ANNE,WACHS, FRANK-PETER,ZHAO, MING
申请号:
ES10179127
公开号:
ES2546093T3
申请日:
2002.09.19
申请国别(地区):
ES
年份:
2015
代理人:
摘要:
Use of VEGF for the manufacture of a medicament for alleviating a symptom of a nervous system disease or disorder in a patient suffering from the central nervous system disease or disorder; wherein the nervous system disease or disorder is selected from the group consisting of neurodegenerative disorders, neurocytoblast disorders, neural progenitor cell disorders, ischemic disorders, neurological trauma, affective disorders, neuropsychiatric disorders, knowledge and memory disorders , Parkinson's disease and Parkinson's disorders, Hungtinton's disease, Alzheimer's disease, amyotrophic lateral sclerosis, spinal ischemia, ischemic stroke, spinal cord injury, cancer-related brain / spinal cord injury, schizophrenia and other psychoses, depression, depression / bipolar disorder, anxiety syndromes / disorders, phobias, stress and related syndromes, cognitive function disorders, aggression, drug dependence and alcoholism, obsessive compulsive behavior syndromes, seasonal mood disorder, borderline personality disorder, cerebral palsy, drug lifestyle-related, multi-infarct dementia, Lewy body dementia, geriatric / age-related dementia, epilepsy and epilepsy-related injury, spinal cord injury, brain injury, brain / spinal cord-related injury trauma, brain tissue / spinal cord injury related to cancer treatment, brain / spinal cord injury related to infection and inflammation, brain / spinal cord injury related to environmental toxin, multiple sclerosis, autism, disorders due to attention deficit, narcolepsy and sleep disorders; and in which, after administration, VEGF induces the proliferation or differentiation in situ of a neurocytoblast or a neural progenitor cell located in the neural tissue of said patient.Utilización de VEGF para la fabricación de un medicamento para aliviar un síntoma de una enfermedad o trastorno del sistema nervioso en un paciente que padece de la enfermedad o trastorno del sistema nervioso central; en la que la enfermedad o trastorno del sistema ne
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充